$CBIO News Article - Catalyst Biosciences Meets th
Post# of 54
(Total Views: 280)
Posted On: 07/08/2019 8:25:45 AM
$CBIO News Article - Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors https://marketwirenews.com/news-releases/cata...65263.html
(0)
(0)Gyre Therapeutics, Inc. (GYRE) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼